As a scientific community, we may now be ready to apply the discovery of potassium channel dysfunction as a key pathophysiologic mechanism underlying PAH to develop new druggable targets in PAH, namely, KCNK3, KATP, and Kv channels; to leverage this molecular mechanism in PAH for rational drug design; and ideally, to advance personalized medicine in patients suffering from PAH in the years to come. This evidence concerns the gene KCNK3 and pulmonary arterial hypertension.